Research Article
COVID-19: A Single-Center ICU Experience of the First Wave in the Philippines
Table 2
Variables and SARS-CoV-2 status.
| | SARS-CoV-2 positive (n = 31) | SARS-CoV-2 negative (n = 60) | Significance (two-tailed) |
| Demographics | | | | Age (years) | 65 (±12) | 65 (±15) | 0.918 | Gender (% of males) | 58.1% | 65% | 0.648 | SAPS-3 | 56.5 (±16.3) | 50.6 (±15.5) | 0.102 | Comorbidities | | | | Neurologic | | | 0.078 | Yes | 2 (6.5%) | 13 (21.7%) | | No | 29 (93.5%) | 47 (78.3%) | | Cardiovascular | | | 0.112 | Yes | 21 (67.7%) | 50 (83.3%) | | No | 10 (32.3%) | 10 (16.7%) | | Pulmonary | | | 0.061 | Yes | 6 (19.4%) | 24 (40%) | | No | 25 (80.6%) | 36 (60%) | | Renal | | | <0.001 | Yes | 2 (6.5%) | 27 (45%) | | No | 29 (93.5%) | 33 (55%) | | Endocrine | | | 0.657 | Yes | 15 (48.4%) | 25 (41.7%) | | No | 16 (51.6%) | 35 (58.3%) | | Autoimmune | | | 0.713 | Yes | 2 (6.5%) | 7 (11.7%) | | No | 29 (93.5%) | 53 (88.3%) | | Malignancy | | | 0.320 | Yes | 2 (6.5%) | 9 (15%) | | No | 29 (93.5%) | 51 (85%) | | Laboratories on ICU admission | | | | Hemoglobin (g/L) | 135 (±17) | 120 (±31) | 0.002 | WBC count (×103/µL) | 8.5 (±4.6) | 13 (±9) | 0.003 | Platelets (×109/L) | 220 (±75) | 238 (±109) | 0.382 | PF ratio | 163 (±103) | 255 (±141) | 0.002 | Lactate (mmoL/L) | 2 (±2) | 2.9 (±2) | 0.113 | Treatment strategy | | | | Hydroxychloroquine | | | <0.001 | Yes | 25 (80.6%) | 9 (15%) | | No | 6 (19.4%) | 51 (85%) | | Tocilizumab | | | <0.001 | Yes | 17 (54.8%) | 2 (3.3%) | | No | 14 (45.2%) | 68 (96.7%) | | Lopinavir/ritonavir | | | 0.006 | Yes | 6 (19.4%) | 1 (1.7%) | | No | 25 (80.6%) | 59 (98.3%) | | CRRT | | | <0.001 | Yes | 18 (58.1%) | 10 (16.7%) | | No | 13 (41.9%) | 50 (83.3%) | | NMBA | | | 0.017 | Yes | 6 (19.4%) | 2 (3.3%) | | No | 25 (80.6%) | 58 (96.7%) | | Prone positioning | | | <0.001 | Yes | 13 (41.9%) | 3 (5%) | | No | 18 (58.1%) | 57 (95%) | | IVIG | | | 0.037 | Yes | 3 (9.7%) | 0 | | No | 28 (90.3%) | 60 (100%) | | HA-330 | | | <0.001 | Yes | 8 (25.8%) | 0 | | No | 23 (74.2%) | 60 (100%) | | Intubation | | | <0.001 | Yes | 29 (93.5%) | 34 (56.7%) | | No | 2 (6.5%) | 26 (43.3%) | | Outcomes | | | <0.001 | ICU survivor | 9 (29%) | 45 (75%) | | ICU mortality | 22 (71%) | 15 (25%) | | Number of days intubated | 13 (±7) | 8 (±7) | 0.005 | Standardized mortality ratio | 2.34 | 1.15 | |
|
|